How well does Opdualag(Nivolumab and Relatlimab) work?

This section summarizes the efficacy data from the pivotal clinical trial.

Therapeutic Efficacy

The efficacy of OPDUALAG was demonstrated in the RELATIVITY-047 trial, a randomized, double-blinded study in patients with previously untreated metastatic or unresectable melanoma. The trial showed a statistically significant improvement in progression-free survival (PFS) compared to nivolumab monotherapy, with a median PFS of 10.1 months versus 4.6 months. The overall response rate was also higher in the OPDUALAG group. The final analysis of overall survival, however, was not statistically significant. This establishes the clinical benefit of the combination therapy in this patient population.